Insiders · ITCI

ITCI insider transactions

Intra-Cellular Therapies Inc. (ITCI) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ITCI insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Intra-Cellular Therapies Inc., latest first. Follow anyone to get their next filing.

• Eduardo Rene SalasDirector, since April 2022
• Rory B RiggsDirector-$14M
• Michael HalsteadPresident-$24.6M
• Robert L Van NostrandDirector-$5.32M
• Mark NeumannEVP, Chief Commercial Officer-$19.3M
• Joel S MarcusDirector-$6.1M
• Sharon MatesChairman and CEO, Director-$69.2M
• Suresh K. DurgamEVP, Chief Medical Officer-$9.7M
• Sanjeev NarulaExecutive Vice President & CFO, since August 2024
• Alexandria Venture Investments, LLCDirector
• Lawrence J. HinelineSVP of Finance, CFO-$26M
• Michael RawlinsDirector, since June 2021
• Richard A LernerDirector
• Christopher D AlafiDirector

Recent Form 3, 4, and 5 filings for ITCI

• 585d
  Director Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  Director Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  President Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  Director Van Nostrand Robert L returned $1,496,880 worth of shares to the company (11,340 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  EVP, Chief Commercial Officer Neumann Mark returned $6,971,052 worth of shares to the company (52,811 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  Director Marcus Joel S returned $7,687,416 worth of shares to the company (58,238 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  Chairman and CEO Mates Sharon returned $149,851,020 worth of shares to the company (1,135,235 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  EVP, Chief Medical Officer Durgam Suresh K. returned $5,664,516 worth of shares to the company (42,913 units at $132.00), closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 586d
  SEC Form 4 filed by Executive Vice President & CFO Narula Sanjeev

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 588d
  Chairman and CEO Mates Sharon gifted 190,000 shares and received a gift of 190,000 shares, decreasing direct ownership by 17% to 945,235 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 609d
  Chairman and CEO Mates Sharon converted options into 61,278 shares and covered exercise/tax liability with 29,977 shares, increasing direct ownership by 3% to 1,135,235 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 609d
  President Halstead Michael converted options into 20,478 shares and covered exercise/tax liability with 10,475 shares, increasing direct ownership by 88% to 21,307 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 609d
  EVP, Chief Medical Officer Durgam Suresh K. converted options into 20,478 shares and covered exercise/tax liability with 8,688 shares, increasing direct ownership by 38% to 42,913 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 609d
  EVP, Chief Commercial Officer Neumann Mark converted options into 20,478 shares and covered exercise/tax liability with 8,688 shares, increasing direct ownership by 29% to 52,811 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 614d
  President Halstead Michael covered exercise/tax liability with 6,261 shares and converted options into 12,239 shares, increasing direct ownership by 112% to 11,304 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 614d
  EVP, Chief Medical Officer Durgam Suresh K. covered exercise/tax liability with 3,709 shares and converted options into 8,742 shares, increasing direct ownership by 19% to 31,123 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 614d
  Chairman and CEO Mates Sharon converted options into 34,969 shares and covered exercise/tax liability with 16,978 shares, increasing direct ownership by 2% to 1,103,934 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 614d
  EVP, Chief Commercial Officer Neumann Mark covered exercise/tax liability with 3,709 shares and converted options into 8,742 shares, increasing direct ownership by 14% to 41,021 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 620d
  Director Marcus Joel S exercised 7,009 shares at a strike of $63.79, increasing direct ownership by 17% to 48,238 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 642d
  Chairman and CEO Mates Sharon covered exercise/tax liability with 15,233 shares and was granted 30,847 shares, increasing direct ownership by 1% to 1,085,943 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 642d
  EVP, Chief Commercial Officer Neumann Mark was granted 11,017 shares and covered exercise/tax liability with 4,729 shares, increasing direct ownership by 21% to 35,988 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 642d
  President Halstead Michael was granted 11,017 shares and covered exercise/tax liability with 5,691 shares (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 642d
  EVP, Chief Medical Officer Durgam Suresh K. was granted 11,017 shares and covered exercise/tax liability with 4,730 shares, increasing direct ownership by 32% to 26,090 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 643d
  SEC Form 4 filed by Executive Vice President & CFO Narula Sanjeev

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 674d
  Director Riggs Rory B was granted 215 shares, increasing direct ownership by 0.16% to 131,512 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 702d
  Chairman and CEO Mates Sharon exercised 102,697 shares at a strike of $12.73 and sold $8,722,501 worth of shares (102,697 units at $84.93) (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 724d
  President Halstead Michael sold $3,692,100 worth of shares (41,583 units at $88.79) and exercised 41,583 shares at a strike of $29.77 (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 755d
  Director Riggs Rory B converted options into 14,189 shares, increasing direct ownership by 12% to 131,297 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 768d
  Director Riggs Rory B was granted 246 shares, increasing direct ownership by 0.21% to 117,108 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 801d
  Chairman and CEO Mates Sharon exercised 70,000 shares at a strike of $12.73 and sold $5,089,236 worth of shares (70,000 units at $72.70) (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 803d
  Chairman and CEO Mates Sharon exercised 95,925 shares at a strike of $17.57 and sold $7,054,085 worth of shares (95,925 units at $73.54) (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 808d
  Chairman and CEO Mates Sharon exercised 121,073 shares at a strike of $17.57 and sold $9,086,738 worth of shares (121,073 units at $75.05) (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 811d
  EVP, Chief Commercial Officer Neumann Mark exercised 18,714 shares at a strike of $36.89 and sold $1,405,047 worth of shares (18,714 units at $75.08) (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 817d
  SEC Form 4 filed by Executive Vice President & CFO Narula Sanjeev

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 817d
  SEC Form 3 filed by new insider Narula Sanjeev

  3 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 859d
  Director Van Nostrand Robert L was granted 83 shares, increasing direct ownership by 0.74% to 11,340 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 859d
  Director Riggs Rory B was granted 262 shares, increasing direct ownership by 0.22% to 116,862 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 867d
  Director Van Nostrand Robert L converted options into 1,567 shares, increasing direct ownership by 16% to 11,257 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 867d
  Director Salas Eduardo Rene converted options into 1,567 shares (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 867d
  Director Marcus Joel S converted options into 1,567 shares, increasing direct ownership by 4% to 41,229 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 867d
  Director Riggs Rory B exercised 21,567 shares at a strike of $15.63 and sold $337,193 worth of shares (4,462 units at $75.57), increasing direct ownership by 17% to 116,600 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 871d
  Director Van Nostrand Robert L exercised 20,000 shares at a strike of $16.86 and sold $1,518,199 worth of shares (20,000 units at $75.91) (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 874d
  SEC Form 4 filed by Director Salas Eduardo Rene

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 874d
  SEC Form 4 filed by Director Riggs Rory B

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 874d
  SEC Form 4 filed by Director Marcus Joel S

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 874d
  SEC Form 4 filed by Director Van Nostrand Robert L

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 928d
  Mates Sharon exercised 20,020 shares at a strike of $17.26, increasing direct ownership by 2% to 1,070,329 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 951d
  Van Nostrand Robert L was granted 79 shares, increasing direct ownership by 0.82% to 9,690 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 951d
  Riggs Rory B was granted 260 shares, increasing direct ownership by 0.26% to 99,495 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 962d
  Riggs Rory B exercised 20,000 shares at a strike of $18.56, increasing direct ownership by 25% to 99,235 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 972d
  Mates Sharon sold $4,048,400 worth of shares (61,277 units at $66.07) and converted options into 20,565 shares, decreasing direct ownership by 4% to 1,050,309 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 972d
  Hineline Lawrence J. sold $1,542,147 worth of shares (23,253 units at $66.32) and exercised 10,121 shares at a strike of $25.44, closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 972d
  Halstead Michael sold $1,353,235 worth of shares (20,477 units at $66.09) and converted options into 7,345 shares, closing all direct ownership in the company (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 972d
  Durgam Suresh K. sold $672,791 worth of shares (10,162 units at $66.21) and converted options into 7,345 shares, decreasing direct ownership by 12% to 19,803 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 972d
  Neumann Mark sold $1,356,110 worth of shares (20,477 units at $66.23) and converted options into 7,345 shares, decreasing direct ownership by 31% to 29,700 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 975d
  Neumann Mark converted options into 13,132 shares, increasing direct ownership by 44% to 42,832 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 975d
  Mates Sharon converted options into 40,712 shares, increasing direct ownership by 4% to 1,091,021 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 975d
  Halstead Michael converted options into 13,132 shares (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 975d
  Hineline Lawrence J. converted options into 13,132 shares (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
• 975d
  Durgam Suresh K. converted options into 13,132 shares, increasing direct ownership by 138% to 22,620 units (SEC Form 4)

  4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)